Venture Partner at Samsara BioCapital · Joined 2018
View Live Interactive Profile →Dr. Robert Stein joined Samsara BioCapital as a Venture Partner in 2018. The firm states he has over 35 years of experience in the pharmaceutical and biotech industry and has played a significant role in the discovery and development of eight marketed drugs, including Sustiva, Fablyn, Viviant, PanRetin, TargRetin, Promacta and Eliquis. He began his career at Merck, Sharp and Dohme Research Laboratories and later held senior management positions including Head of Pharmacology for Merck & Co., CSO and SVP of Research for Ligand Pharmaceuticals, EVP of Research and Preclinical Development for Dupont Merck, President and CSO for Incyte Pharmaceuticals, President of Roche Palo Alto, and CEO of KineMed. He is currently an advisor to Agenus, Inc.'s global research and development efforts; the firm describes this as an advisory relationship rather than a board seat, so no board seat is recorded. He holds an M.D. and a Ph.D. in Physiology and Pharmacology from Duke University.